You just read:

Opportunity for EMD Serono's Mavenclad is Growing in the Relapsing-Remitting Multiple Sclerosis Segment of the Canada Market, Although Increasingly Deferred Treatment Algorithm Positioning Is a Threat That Could Benefit Roche's Ocrevus and Novartis' Gilenya

News provided by

Spherix Global Insights

Nov 19, 2019, 07:00 ET